Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
about
The macrophages in rheumatic diseasesCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaBiological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence.Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.Smoking and outcomes after knee and hip arthroplasty: a systematic reviewManaging cytokine release syndrome associated with novel T cell-engaging therapies.Toxicity management for patients receiving novel T-cell engaging therapies.Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.Immunosuppressive Medications.Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Quality of hip and knee osteoarthritis management in primary health care in a Norwegian county: a cross-sectional survey.Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient.Managing macrophages in rheumatoid arthritis by reform or removal.Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a reviewTocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials.Interleukin 6 and rheumatoid arthritisTocilizumab in the treatment of rheumatoid arthritis and beyond.Hitting a complex target: an update on interleukin-6 trans-signalling.The problem of choice: current biologic agents and future prospects in RA.Rheumatoid arthritis and cardiovascular diseaseIL-6 blockade in chronic inflammatory diseases.Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications.Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.Cardiovascular disease in patients with rheumatoid arthritis.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritisProfiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational studyGuidelines for the drug treatment of rheumatoid arthritis.Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.Profile of tocilizumab and its potential in the treatment of giant cell arteritis.Lipids in RA: Is Less Not Necessarily More?Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis
P2860
Q26765275-564F9F14-1DA8-4062-B642-39899929CDC5Q28084879-6E7CE90C-108D-49E8-B89B-AF30D659F5B3Q30872562-635E4773-32DB-474A-B389-568229211786Q33432572-4F68414D-B962-4516-9F3F-8659A8648AEEQ33774610-D24F7300-F1B8-42E4-8469-77A2E578BBBDQ33776622-5031D496-D475-40F4-9E10-284F188E891AQ33993517-2733DDB6-64F9-4E25-B8AA-5BC4F930F99BQ34343346-134C17FC-9618-4667-A004-89758DBFFA9CQ34465354-E1E4B287-7CF9-497E-B3E1-EFC3B5D63243Q34484801-D7EDEEA3-0210-47A7-82CB-428796395246Q34523450-1F31A4B9-54C8-4FD0-B90D-CA2E6EC21A91Q34611903-A4C0412B-C15B-4A76-B419-F5686153B400Q34763844-FA855238-45A3-46C3-B640-5527FD6A86B6Q35135726-F6D7CF07-828D-41B7-82C6-F87A7F36F740Q35415667-09531939-79A3-4BFC-A0E9-717361A7C40CQ35564852-6D14D0E9-2460-4EEC-BA55-CA29DA5C2F45Q36464352-B24363CF-E5DB-4074-9E90-A3C82E641CD6Q36490257-F49C15A8-DDA4-4411-9463-232FEF9DEAA7Q36802184-1E8868F1-9B1A-4217-86A3-65D3835B9599Q36812587-C953C492-EFB2-4439-AB77-E9A8E5C758ECQ36996859-0C7DE2D4-3703-4917-A0C8-75F4EBDFCDD8Q37278384-4347F974-E9ED-4B82-BD4B-F1E829E1F665Q37553940-95FA5B6A-9B86-4D22-8B41-903C3DBEDFA1Q37682799-A9C2DCE5-029C-4D9B-8244-68BB1A26DBFFQ37983123-8082236D-2D8C-4B4C-BDA1-E6F6E6A8AD10Q38082588-D9F10840-DC67-42A1-9AE4-7B753B84CAE0Q38149252-C573995B-CF84-49D5-9146-B1F724C4A6B8Q38261783-F38FC633-270C-430B-B8ED-B27DB252A636Q38304259-02D2BBF9-BAD6-41B6-A63B-6EFAD0908C6EQ38309810-A510A97D-DE2D-466F-8DB9-01192E19D10EQ38950371-DD93F21A-231C-4834-87B3-22AA244C99B3Q39256918-3CC675E0-7CE8-4CA1-AB35-59F6FE5235F2Q41176187-E8DDFF6D-AD4D-4D4D-A005-6940EED31292Q41933635-13BE597E-9749-4AF3-97D2-47D922C5E619Q42272947-3627795F-2CC2-4AE4-9CAB-289FAAECBC47Q43675571-ABFB9757-D2B1-4DA6-A0F1-05B9BC677003Q47655158-8DDB3F1D-9DC9-42C6-9935-9B3F26180036Q49215677-0F504D87-1108-4EA5-9F86-189BD49BBD2CQ49721726-5D923A64-8A50-41B7-B87D-3F88353B2A81Q57307072-0BE47308-70E8-4AD3-93C3-5493A1526867
P2860
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@en
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@nl
type
label
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@en
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@nl
prefLabel
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@en
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@nl
P356
P1476
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
@en
P2093
P356
10.3899/JRHEUM.100717
P407
P577
2010-10-15T00:00:00Z